Extract
Aventis Reports Full-Year Results for 2002.
Business Editors
STRASBOURG, France--(BUSINESS WIRE)--Feb. 5, 2003 Aventis, (AVE)(AVEP.PA)(AVEP.FK) - Aventis meets ambitious growth targets for third consecutive year despite a more challenging market and industry environment in 2002: Core business sales activity rises 11.6% and net income climbs 28% Core business EPS rises 27% to EUR 2.62 (EUR 3.31 before goodwill amortization) U.S. sales activity increases 21.4%, strategic brands sales activity rises 28.3% - Product leadership reinforced in key therapeutic areas and complemented by successful introduction of future growth drivers: Lantus and Ketek continue successful roll-out in key markets Aventis plans to submit several new drugs for approval in 2003/2004 New products expected to contribute significantly to sales growth between 2002 and 2007 - Aventis expects continued strong earnings growth in 2003 and beyond Financial flexibility to further strengthen the pharmaceutical business of Aventis Aventis today reported consolidated group net sales of EUR 20.622 billion for 2002 compared with EUR 22.941 billion in 2001. This decline in group sales is attributable to structural changes and the divestment of non-core activities, mainly Aventis CropScience ...See the full content of this document
Sponsored links
